Intellectual Property
Addressing Life-Threatening Diseases with Significant Unmet Need & Limited Treatment Options
At Kairos Pharma, we are dedicated to tackling life-threatening diseases that lack effective treatment options. By leveraging cutting-edge research and a strong intellectual property portfolio, we focus on developing innovative therapies that address significant unmet medical needs.
Every step of our journey is guided by a commitment to delivering impactful solutions for those who need them most.
Key IP generated from Bhowmick, Murali, and Yu Labs
Published patents executed internationally
Exclusive, worldwide rights to IP licensed from Cedars Sinai Medical Center
Pub #
KROS 401
PCT/US2016/035318
KROS 401
PCT/US2015/050906
KROS 401
PCT/US2019/045478
KROS 401
PCT/US2020/045570
KROS 401
PCT/US2017/037558
Title
Methods And Use Of Compounds That Bind To RELA Of NF-KB
Compositions And Methods For Treating Fibrosis
Compositions And Methods For Treating Cancer And Autoimmune Diseases
Method Of Generating Activated T Cells For Cancer Therapy
Sensitization Of Tumors To Therapies Through Endoglin Antagonism
Related links
Technologies
Explore our innovative technologies, advanced platforms, and groundbreaking solutions driving breakthroughs in cancer treatment and addressing critical unmet medical needs.
Pipeline
Explore our drug development pipeline, showcasing innovative therapies and cutting-edge technologies aimed at addressing unmet medical needs and transforming patient outcomes.
Investors
Access key investor information, financial updates, strategic plans, and insights into our mission to drive innovation and deliver transformative therapies in cancer research and treatment.
Intellectual Property
Addressing Life-Threatening Diseases with Significant Unmet Need & Limited Treatment Options
At Kairos Pharma, we are dedicated to tackling life-threatening diseases that lack effective treatment options. By leveraging cutting-edge research and a strong intellectual property portfolio, we focus on developing innovative therapies that address significant unmet medical needs.
Every step of our journey is guided by a commitment to delivering impactful solutions for those who need them most.
Key IP generated from Bhowmick, Murali, and Yu Labs
Published patents executed internationally
Exclusive, worldwide rights to IP licensed from
Cedars Sinai Medical Center
KROS 401
PCT/US2016/035318
Methods And Use Of Compounds That Bind To RELA Of NF-KB
KROS 401
PCT/US2015/050906
Compositions And Methods For Treating Fibrosis
KROS 401
PCT/US2019/045478
Compositions And Methods For Treating Cancer And Autoimmune Diseases
KROS 401
PCT/US2020/045570
Method Of Generating Activated T Cells For Cancer Therapy
KROS 401
PCT/US2017/037558
Sensitization Of Tumors To Therapies Through Endoglin Antagonism
Related links
Technologies
Explore our innovative technologies, advanced platforms, and groundbreaking solutions driving breakthroughs in cancer treatment and addressing critical unmet medical needs.
Pipeline
Explore our drug development pipeline, showcasing innovative therapies and cutting-edge technologies aimed at addressing unmet medical needs and transforming patient outcomes.
Investors
Access key investor information, financial updates, strategic plans, and insights into our mission to drive innovation and deliver transformative therapies in cancer research and treatment.
Intellectual Property
Addressing Life-Threatening Diseases with Significant Unmet Need & Limited Treatment Options
At Kairos Pharma, we are dedicated to tackling life-threatening diseases that lack effective treatment options. By leveraging cutting-edge research and a strong intellectual property portfolio, we focus on developing innovative therapies that address significant unmet medical needs. Our mission is to bring hope to patients by transforming the future of care through scientific breakthroughs and protected advancements.
Every step of our journey is guided by a commitment to delivering impactful solutions for those who need them most.
Key IP generated from Bhowmick, Murali, and Yu Labs
Published patents executed internationally
Exclusive, worldwide rights to IP licensed from Cedars Sinai Medical Center
KROS 401
PCT/US2016/035318
Methods And Use Of Compounds That Bind To RELA Of NF-KB
KROS 401
PCT/US2015/050906
Compositions And Methods For Treating Fibrosis
KROS 401
PCT/US2019/045478
Compositions And Methods For Treating Cancer And Autoimmune Diseases
KROS 401
PCT/US2020/045570
Method Of Generating Activated T Cells For Cancer Therapy
KROS 401
PCT/US2017/037558
Sensitization Of Tumors To Therapies Through Endoglin Antagonism
Related links
Technologies
Pipeline
Explore our drug development pipeline, showcasing innovative therapies and cutting-edge technologies aimed at addressing unmet medical needs and transforming patient outcomes.
Investors
Access key investor information, financial updates, strategic plans, and insights into our mission to drive innovation and deliver transformative therapies in cancer research and treatment.
